Dr. Benham Tehrani of Inova Heart and Vascular Institute explains an After Action Review (AAR) program to evaluate the shock program at his hospital. Watch the video to learn how to initiate an AAR program. Subscribe, tweet this or join the conversation by following us on Twitter: @ProtectedPCI. NPS-097-17
Category: Cardiogenic Shock
- Dr. Alexander Truesdell of the INOVA Heart and Vascular Institute discusses how physicians can apply the same shock management principles found on the battlefront into everyday surgical practice.
- Early recognition of shock and early revascularization are two essential elements of successful treatment for shock on the battlefield as well as in conventional care centers.
The Association Between Obesity and In-Hospital Mortality in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction
- Obesity is paradoxically associated with favorable mortality outcomes in acute myocardial infarction (AMI).
- Association between obesity and in-hospital mortality among patients with cardiogenic shock (CS) complicating AMI (N=290,894) was retrospectively studied.
- Obese patients had lower in-hospital mortality compared with nonobese patients (28.2% vs 36.5%, respectively), but key baseline differences in the obese group may explain this association.
Dr. Sal Mannino and a multi-disciplinary team successfully implemented a cardiogenic shock algorithm at a very busy tertiary center, to move away from unilateral decision-making and to serve as a guide for physicians, nurses, and other healthcare providers. He shares the successes and challenges of creating an algorithm as well as how to best disseminate … Continue reading “Developing a Cardiogenic Shock Protocol and a Heart Team Approach with Dr. Salvatore Mannino”
Data presented by Dr. William O’Neill of Henry Ford Hospital System at the 66th Annual Scientific Session of the American College of Cardiology also included new data from the Detroit Cardiogenic Shock Initiative (DCSI), an unprecedented collaboration between five heart hospitals in Detroit, with the goal of determining whether outcomes in cardiogenic shock can be … Continue reading “Detroit Cardiogenic Shock Initiative: Initial Results”
Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery
Data from Abiomed’s Impella® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late-breaking Featured Clinical Research by Dr. William O’Neill of Henry Ford Hospital System at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, D.C. These data were derived from the IQ Database … Continue reading “Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery”
Announced Wednesday, the Detroit Cardiogenic Shock Initiative (CSI) is an innovative collaboration between five hospital systems in metro Detroit with the goal of determining whether outcomes in cardiogenic shock can be improved by using Impella® as early as possible for patients in the shock spiral. View the Full Story Here Led by Dr. Bill O’Neill … Continue reading “Detroit CSI: Collaboration to Improve Outcomes in Cardiogenic Shock”
Impella 2.5®, Impella CP®, Impella 5.0®, and Impella LD® heart pumps are now FDA indicated to provide treatment of ongoing cardiogenic shock. In this setting, the Impella® heart pumps have the ability to stabilize the patient’s hemodynamics, unload the left ventricle, perfuse the end organs, and allow for recovery of the native heart.
In patients with acute myocardial infarction (AMI), cardiogenic shock (CS) is a primary cause of mortality. According to ACC.org’s “Latest in Cardiology”, AMI with CS presents three main treatment objectives, all of which can be achieved with acute mechanical circulatory support devices: Achieve a mean arterial pressure and vital organ perfusion, Reduce myocardial oxygen demand … Continue reading “Top Cardiogenic Shock Treatment Objectives and Device Options”